My impression was that this - 22 June - video-clip was a big-picture overview which did a nice job of providing exactly that high-level summary.
Details concerning contingency payments - $35 million in total; just $10 million due for the 12 months that end in October 2018 - have been shared previously. They're not secret and generally speaking, the need to pay them reinforces the reality that Elk management purchased a terrific asset at a bargain price.
Details concerning specifics of debt refinancing . . . pending completion of that balance sheet restructuring . . . don't strike me as appropriate for sharing with retail investors. It's enough for me to understand that management are on it; that Elk's considerably stronger balance-sheet will support better lending terms; and that management have previously commented that they expect to generate an incremental $20-plus million in cash-flow on completion of the refinancing.
Dilution becomes a concern only to the extent that the size of the pie remains static or shrinks. Keeping the numbers simple to illustrate, I will far rather own 2 per cent of a watermelon-sized asset than 10 per cent of a peach-sized asset.
The most recent - modest and ongoing - capital-raising exercise offered convenient participation to existing investors. I fully subscribed my own allocation because I support the dual-purpose use of the capital to be raised:
1 - to ensure that the $10 million contingency payment due in October is fully-funded without compromising ongoing organic growth
2 - to fund high-value, short-duration-payback (e.g. 180-days) investments to increase oil-production volumes organically from existing Aneth wells.
I give management a lot of credit for delivery. Consider where Elk was this time last year - just 12 months ago: No Aneth even on the horizon and Grieve not yet in production. Even so the shares traded above 10 cents multiple times during the July-September-17 quarter.
With Elk now a significant producer; with Madden already close to having achieved full pay-back; with Aneth capable of considerable organic growth; and with Grieve now producing and set to grow production further in the near-term . . . Elk shares strike me as a screaming-buy at today's sub-8-cents close.
Just my opinion - a somewhat educated opinion as I have done a bit of homework on this counter - but the answers to your "remaining questions" are definitely and absolutely!
Repeating myself, I just subscribed for the full allocation of shares made available under the current capital-raising exercise and am confident that this will prove to have been a profitable investment on my part.
- Forums
- ASX - By Stock
- ELK
- Ann: Managing Director Video Interview with Boardroom Media
Ann: Managing Director Video Interview with Boardroom Media, page-3
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ELK (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online